Treatment - Page 18 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Evaluating the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX/CAPOX treatment after surgery in patients with stage 3 colon cancer.

Evaluating the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX/CAPOX treatment after surgery in patients with stage 3 colon cancer.

Posted by on Oct 13, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) treatment after surgery in patients with stage 3 colon cancer. The data showed that 3-month modified FOLFOX/CAPOX treatment was as effective and safe as...

Read More

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with diabetes and erectile dysfunction.

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with diabetes and erectile dysfunction.

Posted by on Oct 7, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study evaluated the effectiveness and safety of low-intensity extracorporeal shock wave therapy (Li-ESWT) for patients with diabetes and erectile dysfunction (ED). The data showed that Li-ESWT was safe and effective in improving the symptoms of ED in these patients. Some background Erectile dysfunction (ED) consists of the inability...

Read More

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with diabetes and erectile dysfunction.

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with diabetes and erectile dysfunction.

Posted by on Oct 7, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness and safety of low-intensity extracorporeal shock wave therapy (Li-ESWT) for patients with diabetes and erectile dysfunction (ED). The data showed that Li-ESWT was safe and effective in improving the symptoms of ED in these patients. Some background Erectile dysfunction (ED) consists of the inability...

Read More

Comparing the effectiveness of microdissection testicular sperm extraction versus multiple needle-pass percutaneous testicular sperm aspiration in infertile men with non-obstructive azoospermia.

Comparing the effectiveness of microdissection testicular sperm extraction versus multiple needle-pass percutaneous testicular sperm aspiration in infertile men with non-obstructive azoospermia.

Posted by on Oct 7, 2022 in Infertility | 0 comments

In a nutshell This study directly compared the effectiveness of microdissection testicular sperm extraction (mTESE) versus multiple needle-pass percutaneous testicular sperm aspiration (TESA) in infertile men with non-obstructive azoospermia (NOA). The data showed that the sperm retrieval rate was higher with mTESE than with multiple needle-pass...

Read More

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Posted by on Oct 7, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...

Read More

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Posted by on Oct 7, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICIs) between randomized and real-world studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma. The data showed that ICIs were similarly effective and safe in both randomized and real-world studies for these patients. Some background...

Read More

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Posted by on Oct 7, 2022 in Melanoma | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICIs) between randomized and real-world studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma. The data showed that ICIs were similarly effective and safe in both randomized and real-world studies for these patients. Some background...

Read More

Evaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.

Evaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.

Posted by on Oct 7, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding short-term androgen deprivation therapy (ADT) with or without pelvic lymph node radiotherapy (PLNRT) to prostate bed salvage radiotherapy (PBRT) after surgery in patients with prostate cancer (PC). The study found that adding short-term ADT and PLNRT to PBRT significantly improved...

Read More

Evaluating the effectiveness of first-line treatments in the elderly and non-elderly patients with advanced EGFR-mutated NSCLC.

Evaluating the effectiveness of first-line treatments in the elderly and non-elderly patients with advanced EGFR-mutated NSCLC.

Posted by on Oct 7, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of different first-line treatments in elderly and non-elderly patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The data showed that osimertinib (Tagrisso) was the best treatment regimen to improve survival without cancer worsening in elderly...

Read More

Comparing the effectiveness and safety of short-term versus long-term dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk.

Comparing the effectiveness and safety of short-term versus long-term dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk.

Posted by on Oct 7, 2022 in Coronary artery disease | 0 comments

In a nutshell This study compared the effectiveness and safety of short-term versus long-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) using drug-eluting stents (DES) in patients at high bleeding risk. The data showed that short-term DAPT significantly reduced the risk of bleeding compared with long-term DAPT...

Read More

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Posted by on Sep 30, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) given after surgery in patients with stage II melanoma. The data showed that pembrolizumab given after surgery for up to 1 year significantly reduced the risk of cancer recurrence or death in these patients. Some background Melanoma is one of the most...

Read More

Comparing the effectiveness and safety of single-dose versus multiple-dose GnRH agonist for luteal-phase support in patients undergoing IVF/ICSI cycles.

Comparing the effectiveness and safety of single-dose versus multiple-dose GnRH agonist for luteal-phase support in patients undergoing IVF/ICSI cycles.

Posted by on Sep 29, 2022 in Infertility | 0 comments

In a nutshell This study compared the effectiveness and safety of single-dose (DS) versus multiple-dose (MD) GnRH agonist protocol for luteal phase support in patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. The data showed that the MD protocol was more effective in increasing the live birth and...

Read More